CytomX Therapeutics Inc (NASDAQ: CTMX) on Tuesday, soared 3.96% from the previous trading day, before settling in for the closing price of $2.27. Within the past 52 weeks, CTMX’s price has moved between $0.40 and $3.10.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The company achieved an average annual earnings per share of -124.50%. With a float of $103.99 million, this company’s outstanding shares have now reached $157.54 million.
The extent of productivity of a business whose workforce counts for 121 workers is very important to gauge. In terms of profitability, gross margin is 64.9%, operating margin of 24.37%, and the pretax margin is 28.35%.
CytomX Therapeutics Inc (CTMX) Insider Updates
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of CytomX Therapeutics Inc is 33.99%, while institutional ownership is 35.39%. The most recent insider transaction that took place on Jun 16 ’25, was worth 28,540. In this transaction Chief Financial Officer of this company sold 10,614 shares at a rate of $2.69, taking the stock ownership to the 226,271 shares. Before that another transaction happened on Jun 13 ’25, when Company’s Chief Financial Officer sold 1,641 for $2.95, making the entire transaction worth $4,841. This insider now owns 199,385 shares in total.
CytomX Therapeutics Inc (CTMX) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around -124.50% per share during the next fiscal year.
CytomX Therapeutics Inc (NASDAQ: CTMX) Trading Performance Indicators
CytomX Therapeutics Inc (CTMX) is currently performing well based on its current performance indicators. A quick ratio of 1.73 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 2.52.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 0.50, a number that is poised to hit -0.06 in the next quarter and is forecasted to reach -0.41 in one year’s time.
Technical Analysis of CytomX Therapeutics Inc (CTMX)
The latest stats from [CytomX Therapeutics Inc, CTMX] show that its last 5-days average volume of 2.27 million was inferior to 3.48 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 47.65%.
During the past 100 days, CytomX Therapeutics Inc’s (CTMX) raw stochastic average was set at 72.73%, which indicates a significant increase from 27.94% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 102.44% in the past 14 days, which was lower than the 170.41% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.90, while its 200-day Moving Average is $1.17. Now, the first resistance to watch is $2.44. This is followed by the second major resistance level at $2.53. The third major resistance level sits at $2.67. If the price goes on to break the first support level at $2.21, it is likely to go to the next support level at $2.07. Assuming the price breaks the second support level, the third support level stands at $1.98.
CytomX Therapeutics Inc (NASDAQ: CTMX) Key Stats
Market capitalization of the company is 371.81 million based on 80,621K outstanding shares. Right now, sales total 138,100 K and income totals 31,870 K. The company made 50,920 K in profit during its latest quarter, and 23,530 K in sales during its previous quarter.
